AxoGen (AXGN +6.7%) is up on modestly higher volume in apparent response to the purchase of 75K common shares at $13.499 by CEO Karen Zaderej.
The company is developing a suite of products for nerve repair and protection. Enrollment in a pivotal study, RECON, evaluating its Avance Nerve Graft in patients with digital injuries should be completed by next summer (investor presentation, slide #22).
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.